Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing W… (NCT04914247) | Clinical Trial Compass
APPROVED_FOR_MARKETINGNot Applicable
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
Plain-language summary
The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.